|
1
|
Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
|
Nature
|
2005
|
19.56
|
|
2
|
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
|
J Clin Oncol
|
2008
|
4.45
|
|
3
|
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.
|
Mol Cell Biol
|
2004
|
2.49
|
|
4
|
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
|
Clin Cancer Res
|
2005
|
2.37
|
|
5
|
Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23.
|
Nat Genet
|
2002
|
2.23
|
|
6
|
The type III TGF-beta receptor suppresses breast cancer progression.
|
J Clin Invest
|
2006
|
2.06
|
|
7
|
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
|
Cancer Res
|
2007
|
1.92
|
|
8
|
Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia.
|
PLoS Genet
|
2011
|
1.90
|
|
9
|
Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene.
|
Cancer Cell
|
2003
|
1.76
|
|
10
|
Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression.
|
Cancer Res
|
2006
|
1.74
|
|
11
|
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.73
|
|
12
|
High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
|
Gynecol Oncol
|
2005
|
1.71
|
|
13
|
Gene expression patterns that characterize advanced stage serous ovarian cancers.
|
J Soc Gynecol Investig
|
2004
|
1.68
|
|
14
|
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.
|
Cancer Res
|
2009
|
1.59
|
|
15
|
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.
|
Cancer
|
2010
|
1.53
|
|
16
|
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.
|
Breast Cancer Res Treat
|
2009
|
1.46
|
|
17
|
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.
|
PLoS One
|
2008
|
1.43
|
|
18
|
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.
|
Mol Cancer Res
|
2006
|
1.43
|
|
19
|
Analgesic drug use and risk of ovarian cancer.
|
Epidemiology
|
2006
|
1.33
|
|
20
|
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
|
Am J Obstet Gynecol
|
2004
|
1.29
|
|
21
|
Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.
|
PLoS One
|
2010
|
1.28
|
|
22
|
Prediction and uncertainty in the analysis of gene expression profiles.
|
In Silico Biol
|
2002
|
1.27
|
|
23
|
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.
|
J Clin Oncol
|
2005
|
1.23
|
|
24
|
ISG15 as a novel tumor biomarker for drug sensitivity.
|
Mol Cancer Ther
|
2008
|
1.19
|
|
25
|
Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
|
Breast Cancer Res
|
2011
|
1.17
|
|
26
|
Cell cycle progression in G1 and S phases is CCR4 dependent following ionizing radiation or replication stress in Saccharomyces cerevisiae.
|
Eukaryot Cell
|
2004
|
1.16
|
|
27
|
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
|
Clin Cancer Res
|
2009
|
1.16
|
|
28
|
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.
|
Nucleic Acids Res
|
2006
|
1.16
|
|
29
|
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2006
|
1.15
|
|
30
|
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.
|
Gynecol Oncol
|
2009
|
1.15
|
|
31
|
Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers.
|
Int J Gynecol Cancer
|
2012
|
1.14
|
|
32
|
Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
1.14
|
|
33
|
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.
|
Breast Cancer Res
|
2008
|
1.09
|
|
34
|
Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up.
|
J Am Coll Surg
|
2010
|
1.09
|
|
35
|
Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast.
|
Genes Chromosomes Cancer
|
2004
|
1.08
|
|
36
|
Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer.
|
Oncogene
|
2005
|
1.06
|
|
37
|
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
|
Biochem Pharmacol
|
2011
|
1.06
|
|
38
|
Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus.
|
Clin Cancer Res
|
2004
|
1.05
|
|
39
|
A joint analysis of metabolomics and genetics of breast cancer.
|
Breast Cancer Res
|
2014
|
1.04
|
|
40
|
IGF1 (CA)19 repeat and IGFBP3 -202 A/C genotypes and the risk of prostate cancer in Black and White men.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.04
|
|
41
|
Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.
|
Mol Cancer Res
|
2009
|
1.03
|
|
42
|
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.
|
Gynecol Oncol
|
2012
|
1.03
|
|
43
|
Expression signatures of TP53 mutations in serous ovarian cancers.
|
BMC Cancer
|
2010
|
1.02
|
|
44
|
Role of eotaxin-1 signaling in ovarian cancer.
|
Clin Cancer Res
|
2009
|
1.01
|
|
45
|
Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae.
|
PLoS One
|
2009
|
1.00
|
|
46
|
Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells.
|
Cancer Res
|
2006
|
0.99
|
|
47
|
Pooling of case specimens to create standard serum sets for screening cancer biomarkers.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.98
|
|
48
|
Regulation of the metastasis suppressor gene MKK4 in ovarian cancer.
|
Gynecol Oncol
|
2007
|
0.98
|
|
49
|
Do serum biomarkers really measure breast cancer?
|
BMC Cancer
|
2009
|
0.95
|
|
50
|
Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction.
|
PLoS One
|
2008
|
0.94
|
|
51
|
Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation.
|
Cancer Res
|
2007
|
0.92
|
|
52
|
Evaluation of expression based markers for the detection of breast cancer cells.
|
Breast Cancer Res Treat
|
2005
|
0.92
|
|
53
|
Regulator of G protein signaling 5 is highly expressed in parathyroid tumors and inhibits signaling by the calcium-sensing receptor.
|
Mol Endocrinol
|
2011
|
0.91
|
|
54
|
Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.91
|
|
55
|
Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.
|
Int J Cancer
|
2010
|
0.89
|
|
56
|
Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.89
|
|
57
|
Grade-specific prostate cancer associations of IGF1 (CA)19 repeats and IGFBP3-202A/C in blacks and whites.
|
J Natl Med Assoc
|
2007
|
0.87
|
|
58
|
Predictors of variation in serum IGF1 and IGFBP3 levels in healthy African American and white men.
|
J Natl Med Assoc
|
2009
|
0.86
|
|
59
|
No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
0.86
|
|
60
|
Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.
|
Breast Cancer Res Treat
|
2010
|
0.85
|
|
61
|
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
0.84
|
|
62
|
TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein.
|
Mol Cancer Res
|
2004
|
0.84
|
|
63
|
Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk.
|
Gynecol Oncol
|
2005
|
0.83
|
|
64
|
Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism.
|
J Clin Endocrinol Metab
|
2010
|
0.81
|
|
65
|
Refining the role of BRCA1 in combating oxidative stress.
|
Breast Cancer Res
|
2013
|
0.81
|
|
66
|
IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas.
|
Int J Cancer
|
2009
|
0.78
|
|
67
|
Oxidatively modified proteins as plasma biomarkers in breast cancer.
|
Cancer Biomark
|
2013
|
0.77
|
|
68
|
BRCA2 monoclonal antibodies react with differentiating epithelium.
|
Hybrid Hybridomics
|
2002
|
0.75
|